

Supplementary tables

Table S1 The clinic pathological factors of ccRCC patients

Characteristics	Expression of KCNQ1DN		<i>P</i> -value ¹
	Low (15)	High (14)	
<i>Sex</i>			0.81
Male	9	9	
Female	6	5	
<i>Age</i>			0.60
≤60	10	8	
> 60	5	6	
<i>Histological grade</i>			0.92
Low or undiffer	12	11	
Middle or high	3	3	
<i>TNM stage</i>			0.91
I/II	11	10	
III/IV	4	4	

¹Chi-square test.

Table S2. The primer sets used in qPCR

Targets	Forward primers (5'-3')	Reverse primers (5'-3')
<i>h c-Myc</i>	GCAGCTGCTTAGACGCTGGA	CGCAGTAGAAATACGGCTGCAC
<i>h p27</i>	AAATGTTTCAGACGGTTCCC	CATTCCATGAAGTCAGCGATA
<i>h Cyclin D1</i>	CGCCCCACCCCTCCAG	CCGCCCAGACCCTCAGACT
<i>h KCNQ1DN</i>	GCTGGGGTCTTCTCCTGA	CTCTTGTTTTGCTTTCTTCC
<i>h β-actin</i>	GTGAAGGTGACAGCAGTCGGTT	GAAGTGGGGTGGCTTTTAGGA

h: human

Table S3. The sequences of siRNAs

siRNAs	Forward 5'—3'
siKCNQ1DN-1#	GCUGCCUUUGGACCAGAUUTT
siKCNQ1DN-2#	GCCCUUCUGAGAAAGCAAUTT
siNC	UUCUCCGAACGUGUCACGUTT

Figure S1




Figure S1, KCNQ1DN inhibits the survival of RCC cells through downregulating c-Myc. ACHN (**A**) and 786-O (**B**) cells were transfected with the indicated siRNAs or plasmids for 48h. The cell viability was determined by CCK-8 assays. siNC: control siRNA; siKCNQ1DN: siRNA for KCNQ1DN; sic-Myc: siRNA for c-Myc; pcDNA3.1-KCNQ1DN: expression plasmid of KCNQ1DN; pEX-c-Myc: expression plasmid of c-Myc; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$